Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | OGA | O60502 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PHGDH | O43175 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 6/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4708524 | 0.92 | SMN1; SMN2 (0.46) | HSD17B10OGASMN1; SMN2MAPTACACB | |
| SCHEMBL14453013 | 0.92 | SMN1; SMN2 (0.46) | HSD17B10OGASMN1; SMN2MAPTACACB | |
| SCHEMBL5849758 | 0.92 | SMN1; SMN2 (0.46) | HSD17B10OGASMN1; SMN2MAPTACACB | |
| SCHEMBL4712115 | 0.90 | OGA (0.48) | HSD17B10OGASMN1; SMN2MAPTNOTUM | |
| SCHEMBL14452971 | 0.87 | OGA (0.48) | OGAMAPTCCR1 | |
| SCHEMBL4710337 | 0.87 | OGA (0.46) | HSD17B10OGASMN1; SMN2MAPT | |
| SCHEMBL4709856 | 0.84 | OGA (0.48) | OGA | |
| SCHEMBL4710459 | 0.83 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2MAPTPHGDHNOTUM | |
| SCHEMBL6623525 | 0.81 | MAPT (0.39) | HSD17B10OGASMN1; SMN2MAPTPHGDH | |
| SCHEMBL4709593 | 0.80 | HIF1A (0.46) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1935885-A2 | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. | NEUROGEN CORPORATION (US) | 2008-06-25 | — | — | EP | claimed |
| US-7241765-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2007-07-10 | — | — | US | claimed |
| US-20060229298-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | HUTCHISON ALAN | 2006-10-12 | — | — | US | claimed |
| EP-1389189-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-02-18 | — | — | EP | claimed |
| WO-2002094799-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2002-11-28 | — | — | WO | claimed |
| EP-1935885-A2 | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. | NEUROGEN CORPORATION (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080044353-A1 | Combination Therapy for Weight Management | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
| EP-1729762-A4 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-7241765-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241765-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241765-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1729762-A2 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060229298-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | HUTCHISON ALAN | 2006-10-12 | — | — | US | disclosed |
| US-7081458-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORP. (US) | 2006-07-25 | — | — | US | disclosed |
| WO-2005094305-A2 | COMBINATION THERAPY FOR WEIGHT MANAGEMENT | NEUROGEN CORPORATION (US) | 2005-10-13 | — | — | WO | disclosed |
| US-6953801-B2 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | NEUROGEN CORPORATION (US) | 2005-10-11 | — | — | US | disclosed |
| US-20050182068-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | HUTCHISON ALAN (US) | 2005-08-18 | — | — | US | disclosed |
| US-20050065162-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION | 2005-03-24 | — | — | US | disclosed |
| EP-1389189-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002094799-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | NEUROGEN CORPORATION (US) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044353-A1 | Combination Therapy for Weight Management | CNR1, CNR2, MCHR1 | HSD17B10 1398/4885OGA 1626/4885SMN1; SMN2 1643/4885 |
| US-20060229298-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | MCHR1, MCHR2, MC1R | HSD17B10 1537/4885OGA 4162/4885SMN1; SMN2 1441/4885 |
| US-20050065162-A1 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 1-BENZYL-4-ARYL PIPERAZINE ANALOGUES | MCHR1, MCHR2, MC1R | HSD17B10 1537/4885OGA 4162/4885SMN1; SMN2 1441/4885 |
| US-20050182068-A1 | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues | MCHR1, MCHR2, MC1R | HSD17B10 1537/4885OGA 4162/4885SMN1; SMN2 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.